Edison Open House Video

/in , , /by

Botanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the  2022 Edison Open House: Global Healthcare virtual event this week.

He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs:

“This is a great time to be in dermatology. There’s a real dearth of innovation, and that innovation generally comes from small to medium companies. So we’re aiming to broaden our platform to really provide an M and A target for those larger companies as we move into the next 18 to 24 months.”

2022 Edison Open House: Global Healthcare

/in , , /by

Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.

Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.

Click here to register, it’s free.

Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.

Click here to read the report.

AGM Presentation

/in , , /by

Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual General Meeting (AGM) at 9:00am AWST at the offices of BDO, 38 Station Street, Subiaco, WA.

To coincide with this event, the Company has shared an updated corporate presentation, which consolidates its progress in the past financial year and the valuable opportunities Botanix is pursuing in dermatology and infection control.

Click here to review presentation.

Euroz Hartleys Report | 25 October 2021

/in , , /by

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update.

Click here to view the report.

Euroz Hartleys Report | 29 September 2021

/in , , /by

Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs.

Click here to view the report.

4th International Cannabinoid Derived Pharmaceuticals Summit

/in , , /by

Botanix is delighted to be attending the 4th International Cannabinoid Derived Pharmaceuticals Summit, being held in Boston this week (21-23 September). 

This is the world’s largest conference devoted exclusively to the production of CBD-derived pharmaceuticals for medical conditions. 

Attending industry-leading conferences provides an invaluable opportunity to network with industry peers and key opinion leaders, and to share updates on our leading CBD-based R&D programs in the space of antimicrobial resistance (AMR) and dermatology. 

Find out more about the conference HERE

/in , , /by

Botanix (ASX:BOT) is pleased to share leading stockbroking firm, Euroz Hartleys has initiated coverage of Botanix, with the release of a comprehensive 56-page initial report.

Click here to view the report.

Atopic Dermatitis Update + Presentation

/in , , /by

Botanix Pharmaceuticals has today updated the market with plans for its Atopic Dermatitis (AD) clinical program. This follows important recent learnings on drug dose and formulation design of synthetic CBD in dermatitis applications, together with positive data from a new pilot study conducted in canines with AD.

Canine atopic dermatitis is clinically and immunologically similar to human AD, providing an efficient approach to inform progression of further human studies too.

A recent pilot study of Botanix’s BTX 1204A product in canines (a new higher dose formulation of synthetic CBD for atopic dermatitis, leveraging PermetrexTM), demonstrated significant reductions on average in both the Enhanced Pruritus Score (ESP) and Canine Atopic Dermatitis Extent and Severity Index (CADESI-04) scores over the 28-day treatment period.

Botanix is now advancing plans for a larger BTX 1204A proof of concept canine study in Australia, with goals to confirm and expand safety and efficacy data. Following this, the Company will pursue opportunities for partnering the product in animal health markets and progress towards a Phase 2b study for AD in humans in 1H 2022.

Read today’s ASX release and presentation here.

Investor Conference Call

/in , , /by

Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, and Executive Director, Matt Callahan, hosted an investor conference call on Friday 7 May 2021.

You may listen to the audio file here:

Ticker News Interview

/in , , , /by

Botanix Pharmaceutical’s (ASX:BOT) Executive Director, Matt Callahan, spoke with the Ticker News team yesterday to detail the next phase of our BTX 1801 antimicrobial program, which will target nasal decolonisation of Staph aureus in haemodialysis patients.